Specimen self-collection and HPV DNA screening in a pilot study of 100,242 women


    loading  Checking for direct PDF access through Ovid

Abstract

Since cervical cancer remains common in Mexico despite an established cytology screening program, the Ministry of Health recently introduced pilot front-line HPV testing into the Mexican cervical cancer screening program (CCSP). Here, we present the key field performance metrics of this population-based study. High-risk HPV DNA (hrHPV) testing was conducted on self-collected vaginal specimens from 100,242 women aged 25–75 years residing in Morelos State. All hrHPV positive women and a random sample of 3.2% (n = 2,864) of hrHPV negative participants were referred for colposcopic examination. The main disease endpoint of interest was cervical intraepithelial neoplasia grade 2 or higher (CIN2+). We calculated relative risk, positive predictive value and negative predictive value adjusted for screening test verification bias. The overall prevalence of hrHPV was 10.8% (95%CI 10.6–11.0). Women positive for hrHPV had a relative risk of 15.7 for histologically detectable CIN2+. The adjusted positive predictive value of the hrHPV test was 2.4% (95%CI 2.1–2.7); whereas the adjusted negative predictive value was 99.8% (95%CI 99.8–99.9). These findings suggest that large-scale vaginal hrHPV testing in a middle-income country can identify women at greater risk of advanced cervical abnormalities in a programmatically meaningful way but care is warranted to ensure that disease not detectable at colposcopy is kept to a minimum. PASS shows areas that need improvement and sets the stage for wider use of hrHPV screening of self-collected vaginal specimens in Mexico.What's new?DNA testing for high-risk human papillomavirus (hrHPV) in self-collected vaginal specimens may be useful for the routine detection of cervical precancers. In this investigation of 100,242 women in Mexico, DNA testing of self-collected vaginal specimens was found to have an adjusted positive predictive value of 2.4% and an adjusted negative predictive value of 99.8%. The study sheds light on potential scale-up problems associated with HPV DNA testing and reveals that a triage test is needed to prevent excessive referrals of women to limited colposcopy services.

    loading  Loading Related Articles